Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel NanoVelcro Chip Isolates Intact Circulating Tumor Cells for Diagnostic Testing

By LabMedica International staff writers
Posted on 27 Jan 2015
An international team of bioengineers has developed a novel "nanoVelcro" device that removes circulating tumor cells (CTCs) from the blood without damaging them.

Samples of CTCs are regarded as the “liquid biopsy” of a tumor, providing convenient access to all disease sites, including primary tumor and fatal metastases. More...
A method that preserves the integrity of CTCs allows molecular and functional analyses that can guide proper therapeutic intervention.

Investigators at the University of California, Los Angeles (USA) and colleagues at RIKEN Advanced Science Institute (Japan) recently described a novel "nanoVelcro" chip that selectively removes CTCs from the blood. The NanoVelcro Chip is about the size of a postage stamp and is composed of nanowires coated with antibodies that recognize CTCs. When two milliliters of blood are passed through the chip, the tumor cells adhere to the nanowires like Velcro. Efficiency of CTC binding ranges from 40% to 70%. The cancer cells are retained by tiny temperature-responsive polymer brushes inside the device. At 37 degrees Celsius, these polymer brushes stick to the tumor cells, but when cooled to four degrees Celsius, they release them, allowing analysis of the cells.

The investigators were able to successfully demonstrate culture expansion and mutational analysis of CTCs isolated by this purification system. In addition, they adopted the combined use of the Thermoresponsive NanoVelcro system with downstream mutational analysis to monitor the disease evolution of an index non-small-cell lung cancer (NSCLC) patient, highlighting its translational value in managing NSCLC.

“With our new system, we can control the blood’s temperature—the way coffeehouses would with an espresso machine—to capture and then release the cancer cells in great purity,” said senior author Dr. Hsian-Rong Tseng, professor of molecular and medical pharmacology at the University of California, Los Angeles. “We combined the thermoresponsive system with downstream mutational analysis to successfully monitor the disease evolution of a lung cancer patient. This shows the translational value of our device in managing non-small-cell lung cancer with underlying mutations.”

A detailed description of the NanoVelcro Chip was published in the December 13, 2014, online edition of the journal ACS Nano.

Related Links:

University of California, Los Angeles
RIKEN Advanced Science Institute



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.